Patterns	patterns	O	O	O	O
of	of	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
injury	injury	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
methyldopa	methyldopa	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

Twelve	twelve	O	O	O	O
patients	patients	O	O	O	O
with	with	O	O	O	O
liver	liver	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
related	related	O	O	O	O
to	to	O	O	O	O
methyldopa	methyldopa	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
seen	seen	O	O	O	O
between	between	O	O	O	O
1967	1967	O	O	O	O
and	and	O	O	O	O
1977	1977	O	O	O	O
.	.	O	O	O	O

Illness	illness	O	O	O	O
occurred	occurred	O	O	O	O
within	within	O	O	O	O
1	1	O	O	O	O
-	-	O	O	O	O
-9	-9	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
commencement	commencement	O	O	O	O
of	of	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
9	9	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
remaining	remaining	O	O	O	O
3	3	O	O	O	O
patients	patients	O	O	O	O
having	having	O	O	O	O
received	received	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
for	for	O	O	O	O
13	13	O	O	O	O
months	months	O	O	O	O
,	,	O	O	O	O
15	15	O	O	O	O
months	months	O	O	O	O
and	and	O	O	O	O
7	7	O	O	O	O
years	years	O	O	O	O
before	before	O	O	O	O
experiencing	experiencing	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

Jaundice	jaundice	O	DISEASE	OTHERS	I
with	with	O	O	O	O
tender	tender	O	O	O	O
hepatomegaly	hepatomegaly	O	DISEASE	OTHERS	I
,	,	O	O	O	O
usually	usually	O	O	O	O
preceded	preceded	O	O	O	O
by	by	O	O	O	O
symptoms	symptoms	O	O	O	O
of	of	O	O	O	O
malaise	malaise	O	O	OTHERS	I
,	,	O	O	O	O
anorexia	anorexia	O	O	OTHERS	I
,	,	O	O	O	O
nausea	nausea	O	DISEASE	OTHERS	I
and	and	O	O	O	O
vomiting	vomiting	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
upper	upper	O	O	O	O
abdominal	abdominal	O	DISEASE	OTHERS	I
pain	pain	O	DISEASE	OTHERS	I
,	,	O	O	O	O
was	was	O	O	O	O
an	an	O	O	O	O
invariable	invariable	O	O	O	O
finding	finding	O	O	O	O
in	in	O	O	O	O
all	all	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Biochemical	biochemical	O	O	O	O
liver	liver	O	O	O	O
function	function	O	O	O	O
tests	tests	O	O	O	O
indicated	indicated	O	O	O	O
hepatocellular	hepatocellular	O	O	OTHERS	I
necrosis	necrosis	O	DISEASE	OTHERS	I
and	and	O	O	O	O
correlated	correlated	O	O	O	O
with	with	O	O	O	O
histopathological	histopathological	O	O	O	O
evidence	evidence	O	O	O	O
of	of	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
injury	injury	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
spectrum	spectrum	O	O	O	O
of	of	O	O	O	O
which	which	O	O	O	O
ranged	ranged	O	O	O	O
from	from	O	O	O	O
fatty	fatty	O	O	OTHERS	I
change	change	O	O	OTHERS	I
and	and	O	O	O	O
focal	focal	O	O	O	O
hepatocellular	hepatocellular	O	O	OTHERS	I
necrosis	necrosis	O	DISEASE	OTHERS	I
to	to	O	O	O	O
massive	massive	O	DISEASE	OTHERS	I
hepatic	hepatic	O	DISEASE	OTHERS	I
necrosis	necrosis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Most	most	O	O	O	O
patients	patients	O	O	O	O
showed	showed	O	O	O	O
moderate	moderate	O	O	O	O
to	to	O	O	O	O
severe	severe	O	O	O	O
acute	acute	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
or	or	O	O	O	O
chronic	chronic	O	O	OTHERS	I
active	active	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
with	with	O	O	O	O
associated	associated	O	O	O	O
cholestasis	cholestasis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
drug	drug	O	O	O	O
was	was	O	O	O	O
withdrawn	withdrawn	O	O	O	O
on	on	O	O	O	O
presentation	presentation	O	O	O	O
to	to	O	O	O	O
hospital	hospital	O	O	O	O
in	in	O	O	O	O
11	11	O	O	O	O
patients	patients	O	O	O	O
,	,	O	O	O	O
with	with	O	O	O	O
rapid	rapid	O	O	O	O
clinical	clinical	O	O	O	O
improvement	improvement	O	O	O	O
in	in	O	O	O	O
9	9	O	O	O	O
.	.	O	O	O	O

One	one	O	O	O	O
patient	patient	O	O	O	O
died	died	O	O	O	O
,	,	O	O	O	O
having	having	O	O	O	O
presented	presented	O	O	O	O
in	in	O	O	O	O
hepatic	hepatic	O	DISEASE	OTHERS	I
failure	failure	O	DISEASE	OTHERS	I
,	,	O	O	O	O
and	and	O	O	O	O
another	another	O	O	O	O
,	,	O	O	O	O
who	who	O	O	O	O
had	had	O	O	O	O
been	been	O	O	O	O
taking	taking	O	O	O	O
methyldopa	methyldopa	CHEMICALS	O	OTHERS	I
for	for	O	O	O	O
7	7	O	O	O	O
years	years	O	O	O	O
,	,	O	O	O	O
showed	showed	O	O	O	O
slower	slower	O	O	O	O
clinical	clinical	O	O	O	O
and	and	O	O	O	O
biochemical	biochemical	O	O	O	O
resolution	resolution	O	O	O	O
over	over	O	O	O	O
a	a	O	O	O	O
period	period	O	O	O	O
of	of	O	O	O	O
several	several	O	O	O	O
months	months	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
remaining	remaining	O	O	O	O
patient	patient	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
series	series	O	O	O	O
developed	developed	O	O	O	O
fulminant	fulminant	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
when	when	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
was	was	O	O	O	O
accidentally	accidentally	O	O	O	O
recommenced	recommenced	O	O	O	O
1	1	O	O	O	O
year	year	O	O	O	O
after	after	O	O	O	O
a	a	O	O	O	O
prior	prior	O	O	O	O
episode	episode	O	O	O	O
of	of	O	O	O	O
methyldopa-induced	methyldopa-induced	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
.	.	O	O	O	O

In	in	O	O	O	O
this	this	O	O	O	O
latter	latter	O	O	O	O
patient	patient	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
in	in	O	O	O	O
2	2	O	O	O	O
others	others	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
causal	causal	O	O	O	O
relationship	relationship	O	O	O	O
between	between	O	O	O	O
methyldopa	methyldopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
hepatic	hepatic	O	O	OTHERS	I
dysfunction	dysfunction	O	O	OTHERS	I
was	was	O	O	O	O
proved	proved	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
recurrence	recurrence	O	O	O	O
of	of	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
within	within	O	O	O	O
2	2	O	O	O	O
weeks	weeks	O	O	O	O
of	of	O	O	O	O
re-exposure	re-exposure	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

